The annual incidence of both pancreatic and liver cancer is outlined below, which translates to a global opportunity of more than US$2 billion for pancreatic treatment and US$1.4 billion for liver cancer assuming a US$25,000 price per dose of OncoSilTM.
https://www.google.com/amp/s/finfeed.com/small-caps/biotech/oncosil-verge-ce-mark-approval/amp/
Ann: Investor Presentation, page-7
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.23M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $29.64K | 5.929M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 26857650 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29274841 | 18 |
View Market Depth
| Last trade - 11.13am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 25.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 2546329 | ||
| Last updated 11.09am 16/05/2024 ? | |||||
| OSL (ASX) Chart |